medscape.com
Cure8 news brief
Why This Matters
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission rates, especially for treatment‑refractory patients, without clear new safety signals so far.
Who Should Pay Attention
Clinicians treating moderate-to-severe Crohn’s disease; patients considering escalation from monotherapy to combination biologic or biologic+small-molecule regimens; IBD researchers and clinical trialists.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
This Medscape feature reviews the growing use of dual-targeted (combination) therapy in Crohn’s disease, summarizing trial results such as SONIC, EXPLORER, and DUET program findings and discussing candidate selection, regimen options, and safety considerations.
Keep In Mind
Most randomized data on dual advanced therapy remain limited. Several cited studies are single-arm, post-hoc analyses, or focus on specific combinations and higher‑risk populations. Ongoing phase 3 trials (DUET ENCORE, VICTRIVA, EXPLORER 2.0) will provide more definitive evidence. Discuss risks and monitoring with your care team before considering combination regimens.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmedscape.com
PublisherMedscape
AuthorsDana J. Lukin, MD, PhD
Indexed viaGoogle News
Source typeWeb article
PublishedJul 31, 2026, 2:03 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Autologous Stem Cell Transplant for Crohn's Disease
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.